Robert Gross1,2,3,4, Scarlett L Bellamy2, Bakgaki Ratshaa3, Xiaoyan Han2, Andrew P Steenhoff3,5, Mosepele Mosepele6, Gregory P Bisson1,2,3. 1. Department of Medicine (ID), University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. 2. Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. 3. Botswana-University of Pennsylvania Partnership, Gaborone, Botswana. 4. Philadelphia Veterans Administration Medical Center, Philadelphia, PA, USA. 5. Children's Hospital of Philadelphia, Philadelphia, PA, USA. 6. Department of Medicine, Faculty of Medicine, University of Botswana, Gaborone, Botswana.
Abstract
AIMS: To determine alcohol use effect on HIV treatment success and whether alcohol use mediates the relation between male sex and treatment failure. DESIGN: Longitudinal cohort study. SETTING: Eight HIV clinics in and near Gaborone, Botswana. PARTICIPANTS: A total of 938 HIV-infected treatment-naive adults initiating regimens containing the antiretroviral medication efavirenz between June 2009 and February 2013, including 478 (51%) males, median age 38 years, and plasma HIV RNA 4.9 log10 copies/ml. MEASUREMENTS: Primary outcome was a composite of treatment failure over 6 months including death, lost to care or plasma HIV RNA > 25 copies/ml. Exposures included alcohol use and gender. FINDINGS: Failure in 339 (36%) participants included 40 (4%) deaths, 194 (21%) lost to care and 105 (11%) with HIV RNA > 25 copies/ml. Both hazardous alcohol use in the past year [adjusted odds ratio (aOR) = 1.4, 95% confidence interval (CI) = 1.0, 1.9] and male sex (aOR = 2.1, 95% CI = 1.5, 2.9) were associated with failure. Hazardous alcohol use in the year prior to enrollment was more common in men (57%) than women (24%), P < 0.001. There was no difference in alcohol use effect on failure between sexes (P for interaction > 0.5). Controlling for hazardous alcohol use did not change the relation between sex and failure. CONCLUSION: Alcohol use among HIV-infected adults in Botswana appears to worsen HIV treatment outcomes. Alcohol use does not appear to have either a mediating or a moderating effect on the relation between gender and HIV treatment outcome failure.
AIMS: To determine alcohol use effect on HIV treatment success and whether alcohol use mediates the relation between male sex and treatment failure. DESIGN: Longitudinal cohort study. SETTING: Eight HIV clinics in and near Gaborone, Botswana. PARTICIPANTS: A total of 938 HIV-infected treatment-naive adults initiating regimens containing the antiretroviral medication efavirenz between June 2009 and February 2013, including 478 (51%) males, median age 38 years, and plasma HIV RNA 4.9 log10 copies/ml. MEASUREMENTS: Primary outcome was a composite of treatment failure over 6 months including death, lost to care or plasma HIV RNA > 25 copies/ml. Exposures included alcohol use and gender. FINDINGS: Failure in 339 (36%) participants included 40 (4%) deaths, 194 (21%) lost to care and 105 (11%) with HIV RNA > 25 copies/ml. Both hazardous alcohol use in the past year [adjusted odds ratio (aOR) = 1.4, 95% confidence interval (CI) = 1.0, 1.9] and male sex (aOR = 2.1, 95% CI = 1.5, 2.9) were associated with failure. Hazardous alcohol use in the year prior to enrollment was more common in men (57%) than women (24%), P < 0.001. There was no difference in alcohol use effect on failure between sexes (P for interaction > 0.5). Controlling for hazardous alcohol use did not change the relation between sex and failure. CONCLUSION:Alcohol use among HIV-infected adults in Botswana appears to worsen HIV treatment outcomes. Alcohol use does not appear to have either a mediating or a moderating effect on the relation between gender and HIV treatment outcome failure.
Authors: Charles H Hinkin; Terry R Barclay; Steven A Castellon; Andrew J Levine; Ramani S Durvasula; Sarah D Marion; Hector F Myers; Douglas Longshore Journal: AIDS Behav Date: 2007-03
Authors: Margaret May; Andrew Boulle; Sam Phiri; Eugene Messou; Landon Myer; Robin Wood; Olivia Keiser; Jonathan A C Sterne; Francois Dabis; Matthias Egger Journal: Lancet Date: 2010-07-15 Impact factor: 79.321
Authors: Robert Gross; Richard Aplenc; Thomas Tenhave; Andrea S Foulkes; Rameshwari Thakur; Mosepele Mosepele; Jeffrey S Barrett; Charles Flexner; Brian L Strom; Gregory Bisson Journal: J Acquir Immune Defic Syndr Date: 2008-11-01 Impact factor: 3.731
Authors: Elinore F McCance-Katz; Valerie A Gruber; George Beatty; Paula J Lum; Petrie M Rainey Journal: J Addict Med Date: 2013 Jul-Aug Impact factor: 3.702
Authors: M X Nguyen; R B Hershow; N A Blackburn; Q X Bui; C A Latkin; H Hutton; G Chander; D Dowdy; K E Lancaster; C Frangakis; T Sripaipan; H V Tran; V F Go Journal: Soc Sci Med Date: 2022-03-11 Impact factor: 5.379
Authors: Sarah B Puryear; Laura B Balzer; James Ayieko; Dalsone Kwarisiima; Judith A Hahn; Edwin D Charlebois; Tamara D Clark; Craig R Cohen; Elizabeth A Bukusi; Moses R Kamya; Maya L Petersen; Diane V Havlir; Gabriel Chamie Journal: AIDS Date: 2020-03-01 Impact factor: 4.632
Authors: Supriya Misra; Haitisha T Mehta; Evan L Eschliman; Shathani Rampa; Ohemaa B Poku; Wei-Qian Wang; Ari R Ho-Foster; Mosepele Mosepele; Timothy D Becker; Patlo Entaile; Tonya Arscott-Mills; Phillip R Opondo; Michael B Blank; Lawrence H Yang Journal: Qual Health Res Date: 2021-03-25
Authors: Jessica E Long; Barbra A Richardson; George Wanje; Kate S Wilson; Juma Shafi; Kishorchandra Mandaliya; Jane M Simoni; John Kinuthia; Walter Jaoko; R Scott McClelland Journal: PLoS One Date: 2020-11-24 Impact factor: 3.240